Skip to content

Default mode network functional connectivity following treatment with conventional antidepressants and (es)ketamine in major depressive disorder: A systematic review

Juliana Lima Constantino, Jesca E. de Jager, Jasper O. Nuninga, Jeanine Kamphuis, Robert A Schoevers, Jens H van Dalfsen

Psychiatry Research Neuroimaging September 17, 2026 DOI: 10.1016/j.pscychresns.2026.112333 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Systematic review Peer reviewed
Population Adults with major depressive disorder across 19 included studies
Interventions Conventional antidepressants Ketamine
Topics Default mode network Depression Esketamine Ketamine
Key findings Conventional antidepressants were associated with heterogeneous changes in default mode network resting-state functional connectivity, some of which related to clinical improvement, whereas ketamine was mostly associated with reductions in DMN rsFC, particularly DMN-limbic connectivity. The authors suggest the two agent classes show largely distinct patterns of DMN modulation and that differential DMN rsFC effects associate with clinical improvement.

Abstract

Antidepressant treatments, including conventional antidepressants and (es)ketamine, may reverse default mode network (DMN) resting-state functional connectivity (rsFC) alterations related to major depressive disorder (MDD). Despite these agents having distinct initial action mechanisms, both likely share downstream effects that lead to structural and functional adaptations in MDD-related neural circuits. Examining the effects of these agents on DMN rsFC can provide insights into network-level effects, advance understanding of network-level mechanisms of treatment response, and generate hypotheses regarding potential neurobiological differences between MDD and treatment-resistant depression populations. A systematic search was performed to retrieve studies investigating changes in DMN rsFC following treatment with conventional antidepressants and (es)ketamine in MDD, including the association with clinical outcomes. Nineteen studies were included, 13 administered conventional antidepressants (N = 546), and six intravenous ketamine (N = 247). Conventional antidepressants were associated with heterogeneous changes in DMN rsFC, some of which related to clinical improvements. Conversely, ketamine mostly related with reductions in DMN rsFC, particularly in DMN-limbic connectivity. While interpretations of current findings are limited by heterogeneity in study populations, treatment regimens, and timing assessments, findings suggest that these agents exhibit mostly distinct patterns of DMN modulation, and that differential effects on DMN rsFC associate with clinical improvements.

Comparable studies

Other systematic reviews and meta-analyses on ketamine for depression, most cited first.

Study Year Design Participants
Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression Participants with major depression in placebo-controlled, double-blind, randomized... 2015 Systematic review and meta-analysis
Side-effects associated with ketamine use in depression: a systematic review. Patients with depression 2018 Systematic review
Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis Adults with unipolar or bipolar major depression 2020 Systematic review and meta-analysis n = 1,877
Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories Patients with major depressive disorder or bipolar depression 2016 Systematic review and meta-analysis n = 588
The use of ketamine as an antidepressant: a systematic review and meta‐analysis People with major depressive disorder or bipolar disorder receiving ketamine infusion 2015 Meta-analysis n = 437

Citations in the library

Explore topics

By condition and practice